Employees Login
Home
About Us
Company Profile
Vision & Mission
Management
Global Presence
Clients & Associates
Corporate Responsibility
News & Events
Products
API
Formulations
CRAM
Products Pipeline
Pharma Machinery
Surgical Products
Facilities
Ankleshwar
Kandla
Dehradun
R & D Center
De-Addiction
E-Store
CTD Dossiers
Careers
Life at Rusan
Why Rusan
Current Openings
Scholorships / Interships
HR Contact
Feedback
General Enquiry / Send Complaints
Contact
Highlights
1994
Rusan Pharma Ltd. incorporated by chairman Dr. Navin Saxena
1996
Inauguration of Research & Development Centre at Rusan's Head Quarter in Mumbai
1997
Rusan Pharma Ltd bags an award for Excellence in Productivity, Quality and Innovation.
Chairman, Dr. Navin Saxena receives "Udyog Ratna" Award from Government of India.
1999
Bulk Drug Manufacturing unit acquired in Ankleshwar, Gujarat
2000
Rusan Pharma Ltd acquires Novartis factory in Kandla Special Economic Zone, Gandhidham, Gujarat.
Rusan Pharma Ltd receives "Chemexcil Award" for Outstanding Export Performance.
2001
Rusan Pharma Ltd Bags Excellence Award from CHEMEXCIL.
2002
Rusan Pharma Ltd starts the concept of
OST
in Ukraine in collaboration with
UNODC
Inaguration of Rusan Pharma's Kandla formulation facility
WHO-GMP accreditation for formulation manufacturing facility in Kandla, received.
Research Centre at Mumbai approved by Ministry of Science and Technology, Government of India.
GMP
accreditation for Bulk Drug manufacturing facility at Ankleshwar received.
2003
UK- MHRA Accreditation for formulation manufacturing facility at Kandla received.
South Africa - MCC Accreditation for formulation manufacturing facility at Kandla received.
Zimbabwe - MCAZ accreditation for formulation manufacturing facility at Kandla received.
COS
for Buprenorphine Hydrochloride received from EDQM.
Rusan makes entry into regulated market of UK and South Africa through the supply of Generics.
2004
Sudan - MOH Accreditation for formulation manufacturing facility at Kandla received.
2005
Rusan Pharma Ltd Exports more than 100 formulation to UK,South Africa, CIS, Asia.
UAE - MOH Accreditation for formulation manufacturing facility at Kandla received.
2006
Uganda-NDA Accreditation for formulation manufacturing facility at Kandla received.
API Plant capacity increased 5 folds, for various molecules.
Land acquired for second formulation facility at Dehradun Uttarakhand.
2007
Renewal of UK- MHRA GMP for Kandla facility.
Rusan bags South Africa TB Tender for four drug and two drug combination.
2008
UK - MHRA-GMP Approval for API plant in Ankleshwar, Gujarat.
COS
for Fentanyl base received from EDQM.
COS
for Buprunorphine base received from EDQM
WHO-GMP
accreditation for formulation manufacturing facility in Dehradun, received.
2009
Inauguration of Dehradun Formulation facility.
2010
COS for Naltrexone Hydrochloride received from EDQM
Pause
Play
|
Up
|
Down
scroll